"Look at all your bills, and figure out what can be cut down or cut out," Lauren Savalle told Newsweek.

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

The latest partnership with U.S. Bank is part of Wisetack's innovative embedded origination program, which has reshaped the bank-fintech relationship model by enabling banks to serve both borrowers ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

We bought a home six years ago, and my husband has refused to pay any money toward the mortgage this whole time. He forced me to pay every payment. We live in California. Is he entitled to half of ...